Mon, March 5, 2012
Sun, March 4, 2012
Sat, March 3, 2012
Fri, March 2, 2012
[ Fri, Mar 02nd 2012 ] - Market Wire
30 p.m. ET
Thu, March 1, 2012
[ Thu, Mar 01st 2012 ] - Market Wire
Mortgage Rates Inch Lower
[ Thu, Mar 01st 2012 ] - Market Wire
la Gestion des paiements
Wed, February 29, 2012
[ Wed, Feb 29th 2012 ] - Market Wire
Top Advertisers & Agencies
Tue, February 28, 2012

Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 7, 2012


//science-technology.news-articles.net/content/2 .. ial-results-conference-call-on-march-7-2012.html
Published in Science and Technology on Wednesday, February 29th 2012 at 8:16 GMT by Market Wire   Print publication without navigation


OMAHA, Neb.--([ ])--Transgenomic, Inc. (OTCBB: TBIO) today announced the following Webcast:

What: Transgenomic, Inc. Fourth Quarter 2011 Financial Results and Business Update Conference Call
When: Wednesday, March 7, 2012 @ 11:30 a.m. Eastern
Where:

[ http://www.transgenomic.com/events.asp?id=6 ]

How: Live over the Internet -- Simply log on to the web at the address above.
Contact: Investor Relations, 402-452-5416

To access the call via telephone, call 800-894-5910 from the U.S. or Canada or 785-424-1052 for international participants and enter conference ID TRANS. A telephone replay will be available from 2:30 p.m. Eastern Time on March 7, 2012 through 11:59 p.m. Eastern Time on March 21, 2012 by dialing 800-727-1367 (domestic) or 402-220-2669 (international).

About Transgenomic, Inc.

Transgenomic, Inc. ([ www.transgenomic.com ]) is a global biotechnology company advancing personalized medicine in cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The company has three complementary business divisions: Transgenomic Pharmacogenomic Services is a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development. Transgenomic Clinical Laboratories specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, and oncology. Transgenomic Diagnostic Tools produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The company actively develops and acquires new technology and other intellectual property that strengthen its leadership in personalized medicine.


Publication Contributing Sources